Mouse FSTL3 Protein

Cat. No. FTS-MM1L3



Description	
Source	Recombinant Mouse FSTL3 Protein is expressed from HEK293 with His tag at the C-Terminus.
	It contains Val24-Val256.
Accession	Q9EQC7
Molecular Weight	The protein has a predicted MW of 26 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Bis- Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation Supplied as 0.22µm filtered solution in PBS (pH 7.4).

Storage Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller


quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Follistatin-like 3 (FSTL3) is a novel cytokine that regulates insulin sensitivity and counteracts activin/myostatin signalling. In the present study, regulation of FSTL3 in renal dysfunction was investigated in both human chronic kidney disease (CKD) and acute kidney dysfunction (AKD). Furthermore, mFSTL3 expression was analysed in insulin-sensitive tissues in a mouse model of CKD.

Assay Data

Bis-Tris PAGE




Mouse FSTL3 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Cat. No. FTS-MM1L3

KAGTUS

Assay Data




The purity of Mouse FSTL3 is greater than 95% as determined by SEC-HPLC.

ELISA Data


Mouse FSTL3, His Tag ELISA

0.02μg Human Activin A, No Tag Per Well



Immobilized Human Activin A, No Tag at 0.2µg/ml (100µl/well) on the plate. Dose response curve for Mouse FSTL3, His Tag with the EC50 of 18.0ng/ml determined by ELISA (QC Test).

SPR Data




Mouse FSTL3, His Tag captured on CM5 Chip via anti-his antibody can bind Human Activin A, No tag with an affinity constant of 53.09 pM as determined in SPR assay (Biacore T200).

Cell Based Assay



Assay Data

Recombinant Mouse FSTL3 Protein Bioactivity



Measured by its ability to neutralize Activinmediated inhibition on MPC11 cell proliferation. The ED50 for this effect is typically 5-25 ng/mL in the presence of 7.5 ng/mL rhActivin A.